Reata Pharmaceuticals (NASDAQ:RETA – Free Report)‘s stock had its “reiterates” rating reiterated by equities researchers at 888 in a research report issued on Wednesday, Benzinga reports. RETA has been the subject of a number of other reports. Stifel Nicolaus lifted their price objective on Reata Pharmaceuticals from $105.00 to $115.00 and gave the company a […]